TY - JOUR
T1 - Clinical application of cascade filtration combined with glassbead adsorbents in cancer patients
AU - Shiozaki, S.
AU - Sakagami, K.
AU - Miyazaki, M.
AU - Matsuoka, J.
AU - Uchida, S.
AU - Saito, S.
AU - Fujiwara, T.
AU - Orita, K.
PY - 1989
Y1 - 1989
N2 - Cascade filtration (CF) was applied to patients with advanced cancers. To selectively remove immunosuppressive factors with molecular weight lower than albumin, adsorbents combined with CF were examined. Among 11 kinds of adsorbents, glassbead adsorbents with pore size of 100Å were the most effective in adsorbing such substances. Clinically, a column packed with glassbead adsorbents was concomitantly used with CF. The second filtrate was passed through the column and returned to the patient. The removal rate of immunosuppressive substances with molecular weight lower than albumin was only 20% by CF alone, but more than 50% by CF combined with glassbead adsorbents. Clinical symptoms such as severe back pain and general malaise were drastically improved during and after therapy. These results suggest that CF combined with glassbead adsorbents is an effective adjunctive modality to cancer therapy.
AB - Cascade filtration (CF) was applied to patients with advanced cancers. To selectively remove immunosuppressive factors with molecular weight lower than albumin, adsorbents combined with CF were examined. Among 11 kinds of adsorbents, glassbead adsorbents with pore size of 100Å were the most effective in adsorbing such substances. Clinically, a column packed with glassbead adsorbents was concomitantly used with CF. The second filtrate was passed through the column and returned to the patient. The removal rate of immunosuppressive substances with molecular weight lower than albumin was only 20% by CF alone, but more than 50% by CF combined with glassbead adsorbents. Clinical symptoms such as severe back pain and general malaise were drastically improved during and after therapy. These results suggest that CF combined with glassbead adsorbents is an effective adjunctive modality to cancer therapy.
UR - http://www.scopus.com/inward/record.url?scp=0024364742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024364742&partnerID=8YFLogxK
U2 - 10.1177/039139888901200610
DO - 10.1177/039139888901200610
M3 - Article
C2 - 2777399
AN - SCOPUS:0024364742
SN - 0391-3988
VL - 12
SP - 400
EP - 404
JO - Life Support Systems
JF - Life Support Systems
IS - 6
ER -